Source: Eur Respir J 2005; 25: 942
Disease area: Pulmonary vascular diseases



Rating:

Share or cite this content

Citations should be made in the following way:
V. V. McLaughlin, O. Sitbon, D. B. Badesch, R. J. Barst, C. Black, N. Galie, M. Rainisio, G. Simonneau, and L. J. Rubin.. Survival with first-line bosentan in patients with primary pulmonary hypertension.. Eur Respir J 2005; 25: 942

Member's Comments

No comment yet.

Related content which might interest you: Survival with first-line bosentan in patients with primary pulmonary hypertension Source: Eur Respir J 2005; 25: 244-249 Year: 2005 A matched pairs analysis of long-term outcomes in first-line i.v. epoprostenol or first-line bosentan treated idiopathic pulmonary arterial hypertension Source: Annual Congress 2010 - Present and future medical management of pulmonary arterial hypertension Year: 2010 Longer-term survival in paediatric patients with idiopathic or familial pulmonary arterial hypertension treated with bosentan Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Sitaxsentan treatment for patients with pulmonary arterial hypertension (PAH) failing bosentan due to lack of efficacy Source: Eur Respir J 2005; 26: Suppl. 49, 476s Year: 2005 Time to combination therapy for sildenfail monotherapy in pulmonary artery hypertension (PAH). A comparison with the reported experience with bosentan Source: Annual Congress 2013 –Pulmonary circulation: clinical treatment Year: 2013 Is survival in patients with severe group 3 pulmonary hypertension influenced by targeted therapy? Source: International Congress 2015 – Pulmonary hypertension: novel clinical insights Year: 2015 Sildenafil effects on 1-year survival of patients with idiopathic pulmonary arterial hypertension (IPAH) Source: Annual Congress 2005 - Treatment of pulmonary arterial hypertension Year: 2005 Efficacy of oral add-on therapy in patients with pulmonary hypertension Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Survival in medically treated chronic thromboembolic pulmonary hypertension patients Source: International Congress 2018 – Chronic thromboembolic pulmonary hypertension Year: 2018 Initial combination therapy with ambrisentan (AMB) and tadalafil (TAD) in treatment naïve patients with pulmonary arterial hypertension (PAH): Efficacy and safety in the AMBITION study intent to treat (ITT) population Source: International Congress 2015 – Pulmonary hypertension: new treatment insights Year: 2015 Bosentan improves 6-minutes-walk-test in patients with inoperable chronic thrombo-embolic pulmonary hypertension (iCTEPH) Source: Eur Respir J 2005; 26: Suppl. 49, 272s Year: 2005 Initial combination therapy with epoprostenol and bosentan in severe pulmonary arterial hypertension Source: Annual Congress 2009 - Pulmonary arterial hypertension Year: 2009 Long-term outcome of patients with portopulmonary hypertension treated with sildenafil Source: Annual Congress 2009 - Pulmonary hypertension Year: 2009 Bosentan added to sildenafil therapy in patients with pulmonary arterial hypertension Source: Eur Respir J 2015; 46: 405-413 Year: 2015 Response to exercise in patients with pulmonary arterial hypertension treated with combination therapy Source: ERJ Open Res, 7 (1) 00725-2020; 10.1183/23120541.00725-2020 Year: 2021 Successful pregnancy outcome in patients with pulmonary arterial hypertension receiving prostayclin therapy Source: Annual Congress 2004 - Pulmonary hypertension Year: 2004 Initial dual oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) Source: International Congress 2018 – Pulmonary hypertension: therapy Year: 2018 Long-term riociguat treatment towards implementing a targeted treatment strategy in patients with idiopathic pulmonary arterial hypertension Source: Virtual Congress 2020 – Epidemiology and treatment of pulmonary arterial hypertension Year: 2020 Diagnosis and treatment of secondary pulmonary hypertension in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 404s Year: 2006 Dipyridamol as adjuvant therapy in patients with pulmonary arterial hypertension (PAH) Source: Eur Respir J 2005; 26: Suppl. 49, 562s Year: 2005